The Spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds

Background: The approach to national and global estimates of HIV/AIDS used by UNAIDS starts with estimates of adult HIV prevalence prepared from surveillance data using either the Estimation and Projection Package (EPP) or the Workbook. Time trends of prevalence are transferred to Spectrum to estimate the consequences of the HIV/AIDS epidemic, including the number of people living with HIV, new infections, AIDS deaths, AIDS orphans, treatment needs and the impact of treatment on survival. Methods: The UNAIDS Reference Group on Estimates, Modelling and Projections regularly reviews new data and information needs and recommends updates to the methodology and assumptions used in Spectrum. The latest update to Spectrum was used in the 2007 round of global estimates. Results: Several new features have been added to Spectrum in the past two years. The structure of the population was reorganised to track populations by HIV status and treatment status. Mortality estimates were improved by the adoption of new approaches to estimating non-AIDS mortality by single age, and the use of new information on survival with HIV in non-treated cohorts and on the survival of patients on antiretroviral treatment (ART). A more detailed treatment of mother-to-child transmission of HIV now provides more prophylaxis and infant feeding options. New procedures were implemented to estimate the uncertainty around each of the key outputs. Conclusions: The latest update to the Spectrum program is intended to incorporate the latest research findings and provide new outputs needed by national and international planners.

[1]  N. French,et al.  Survival and Causes of Death, 2 years after introduction of Antiretroviral Therapy in Africa: a historical cohort comparison in Entebbe, Uganda , 2006 .

[2]  F. Dabis,et al.  Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission , 2005, AIDS.

[3]  N. Sewankambo,et al.  Survival of HIV-infected treatment-naive individuals with documented dates of seroconversion in Rakai, Uganda , 2007, AIDS.

[4]  L. Mofenson,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow up of the HIVNET 012 randomized trial , 2004 .

[5]  G. Maartens,et al.  Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa , 2004, AIDS.

[6]  L. Palombi,et al.  Treatment acceleration program and the experience of the DREAM program in prevention of mother-to-child transmission of HIV , 2007, AIDS.

[7]  Lu Yin,et al.  Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study , 2007, AIDS.

[8]  L. Myer,et al.  Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Whitworth,et al.  HIV-1 disease progression and AIDS-defining disorders in rural Uganda , 1997, The Lancet.

[10]  N. Ford,et al.  Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort , 2006, AIDS.

[11]  J. Bartlett.  Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand , 2004 .

[12]  L. Moulton,et al.  Early exclusive breastfeeding reduces the risk of postnatal HIV-1 transmission and increases HIV-free survival , 2005, AIDS.

[13]  M. Robb,et al.  The Natural History of HIV-1 Infection in Young Thai Men After Seroconversion , 2004, Journal of acquired immune deficiency syndromes.

[14]  C. Khamboonruang,et al.  Risk factors for HIV‐1 transmission from HIV‐seropositive male blood donors to their regular female partners in northern Thailand , 1997, AIDS.

[15]  T Brown,et al.  Progress and challenges in modelling country-level HIV/AIDS epidemics: the UNAIDS Estimation and Projection Package 2007 , 2008, Sexually Transmitted Infections.

[16]  E. Delaporte,et al.  Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study , 2006, AIDS.

[17]  J. Changalucha,et al.  Survival after HIV infection in the pre-antiretroviral therapy era in a rural Tanzanian cohort , 2007, AIDS.

[18]  F. Liégeois,et al.  Field Assessment of Generic Antiretroviral Drugs: A Prospective Cohort Study in Cameroon , 2005, Antiviral therapy.

[19]  C. Feldman,et al.  Characteristics and Outcomes of Adult Patients Lost to Follow-Up at an Antiretroviral Treatment Clinic in Johannesburg, South Africa , 2008, Journal of acquired immune deficiency syndromes.

[20]  P. Sonnenberg,et al.  Estimating ‘net’ HIV-related mortality and the importance of background mortality rates , 2007, AIDS.

[21]  K. Nelson,et al.  Survival of blood donors and their spouses with HIV-1 subtype E (CRF01 A_E) infection in northern Thailand, 1992–2007 , 2007, AIDS.

[22]  M. Wawer,et al.  Trends in HIV‐1 prevalence may not reflect trends in incidence in mature epidemics: data from the Rakai population‐based cohort, Uganda , 1997, AIDS.

[23]  J. Sterne,et al.  Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries , 2006, The Lancet.

[24]  E. Delaporte,et al.  Long-Term Benefits of Highly Active Antiretroviral Therapy in Senegalese HIV-1-Infected Adults , 2005, Journal of acquired immune deficiency syndromes.

[25]  C. Rouzioux,et al.  Long-term survival and immuno-virological response of African HIV-1-infected children to highly active antiretroviral therapy regimens , 2006, AIDS.

[26]  R. Salamon,et al.  Progression to WHO criteria for antiretroviral therapy in a 7-year cohort of adult HIV-1 seroconverters in Abidjan, Côte d'Ivoire. , 2007, Bulletin of the World Health Organization.

[27]  J. Garcia-Calleja,et al.  The 2005 Workbook: an improved tool for estimating HIV prevalence in countries with low level and concentrated epidemics , 2006, Sexually Transmitted Infections.

[28]  Noah Kiwanuka,et al.  Mortality associated with HIV infection in rural Rakai District, Uganda , 2000, AIDS.

[29]  N. Walker,et al.  A global analysis of trends in the quality of HIV sero-surveillance , 2004, Sexually Transmitted Infections.

[30]  N. Ford,et al.  Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment , 2006, The Lancet.

[31]  Basia Zaba,et al.  Survival and mortality of people infected with HIV in low and middle income countries: results from the extended ALPHA network. , 2007, AIDS.

[32]  S. Blanche,et al.  Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Côte d'Ivoire , 2004, AIDS.

[33]  Dorothy Bray,et al.  Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial , 2003, The Lancet.

[34]  D. Cooper,et al.  Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research , 2007, AIDS.

[35]  J. Mary,et al.  Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. , 2004, The New England journal of medicine.

[36]  P. Wright,et al.  Antiretroviral therapy in a thousand patients with AIDS in Haiti. , 2005, The New England journal of medicine.

[37]  John L Sullivan,et al.  A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. , 2003, The Journal of infectious diseases.

[38]  L. Shafer,et al.  HIV-1 disease progression and mortality before the introduction of highly active antiretroviral therapy in rural Uganda , 2007, AIDS.

[39]  Henry S. Shryock,et al.  The Methods and Materials of Demography. , 1973 .

[40]  J. Whitworth,et al.  The natural history of HIV-1 infection in Africa , 2001, Nature Medicine.

[41]  M. Carrasco.  Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa , 2008 .

[42]  K. Nelson,et al.  The natural history of HIV-1 subtype E infection in young men in Thailand with up to 14 years of follow-up , 2007, AIDS.

[43]  N. Walker,et al.  Monitoring the scale-up of antiretroviral therapy programmes: methods to estimate coverage. , 2006, Bulletin of the World Health Organization.

[44]  N. Grassly,et al.  Projecting the demographic impact of AIDS and the number of people in need of treatment: updates to the Spectrum projection package , 2006, Sexually Transmitted Infections.

[45]  E. Karita,et al.  HIV-infected Rwandan women have a high frequency of long-term survival , 2007, AIDS.

[46]  W. Fawzi,et al.  Late postnatal transmission of HIV-1 in breast-fed children: an individual patient data meta-analysis. , 2004, The Journal of infectious diseases.